Drug sedation
Conditions
Interventions
Group 1 :Remazolam benzenesulfonate was administered during induction of anesthesia
Sponsors
Affiliated Hospital of Zunyi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients receiving ERCP treatment; 2. 18 <= Age <= 65 years old, regardless of gender; 3. 18 kg/m2 <= BMI <= 30 kg/m2 4. The American Medical Association (ASA) is classified as I-III.
Exclusion criteria
Exclusion criteria: 1. Used sedatives within 24 hours; 2. Hypertensive patients whose blood pressure has not been satisfactorily controlled by antihypertensive drug therapy (suppressed systolic blood pressure >= 180 mmHg, and/or diastolic blood pressure >= 110 mmHg during the screening period); 3. Patients with serious cardiovascular disease history and myocardial infarction within the last 6 months; 4. Patients with mental system diseases and cognitive dysfunction; 5. Women who are pregnant or breastfeeding; 6. Patients with mental system diseases such as depression, mania and schizophrenia; 7. Patients who are deemed inappropriate to participate in this experiment by the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effective sedative dose of remazolam benzenesulfonate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Vital signs;Mean time from the initiation of remazolam benzenesulfonate to MOAA/S score = 4 points);adverse event; | — |
Countries
China
Contacts
Public ContactZhaoqiong Zhu
Affiliated Hospital of Zunyi Medical University
Outcome results
None listed